( July 17, 2025, 8:57 AM EDT) -- CHICAGO — A federal judge in Illinois granted a motion for summary judgment in favor of the maker of prescription drug Humira and the company’s then chief executives in a case in which shareholders allege that they violated federal securities laws by misleading investors by concealing that two marketing programs were in violation of the Anti-Kickback Statute, which, when revealed, caused the company’s stock to drop; the judge found that the subject programs did not violate the statute and that even if they did, the shareholders couldn’t prove that the defendants concealed the information about the potential anti-kickback violations with purposeful or reckless intent to deceive....